Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Value Type description Interaction Map Rank Network Comparison Type red Gene Filtered green network_comparison
Results: HTML CSV LaTeX
Showing element 232 to 281 of 3228 in total
Value Type: Measured
Interaction Map: High confidence
Network Comparison Type: Divided
Filtered: 1

\def\wcA{0.16666666666667\textwidth}
\def\wcB{0.16666666666667\textwidth}
\def\wcC{0.16666666666667\textwidth}
\def\wcD{0.16666666666667\textwidth}
\def\wcE{0.16666666666667\textwidth}
\begin{longtable}{|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
adp-ribosylation factor-like protein 3. [source:swissprot;acc:p36405]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1534\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5916.05\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6350.53\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07344\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
adp-ribosylation factor-like protein 4. [source:swissprot;acc:p40617]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
883\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
5912.84\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
6517.69\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.10229\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
adp-ribosylation factor-like protein 7 (adp-ribosylation factor-like protein lak). [source:swissprot;acc:p56559]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
881\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
adrenodoxin, mitochondrial precursor (adrenal ferredoxin) (hepatoredoxin) (ferredoxin 1). [source:swissprot;acc:p10109]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
548\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
8268.19\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
9405.85\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.13759\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
af-6 protein. [source:swissprot;acc:p55196]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2076\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5746.65\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6067.27\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05579\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
afg3-like protein 2 (ec 3.4.24.-) (paraplegin-like protein). [source:swissprot;acc:q9y4w6]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1543\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5466\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5865.33\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07306\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
aflatoxin b1 aldehyde reductase 1 (ec 1.-.-.-) (afb1-ar 1) (aldoketoreductase 7). [source:swissprot;acc:o43488]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1141\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
5790.65\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
6303.93\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.08864\vspace{3pt}}}\\\cline{1-2}\cline{4-4}
\parbox{\wcA}{\vspace{3pt}\noindent
aflatoxin b1 aldehyde reductase 2 (ec 1.-.-.-) (afb1-ar 2). [source:swissprot;acc:o95154]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1131\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
6303.92\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ah receptor-interacting protein (aip) (immunophilin homolog ara9) (hbv-x associated protein 2). [source:swissprot;acc:o00170]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1904\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5204.25\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5530.11\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06261\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alanine aminotransferase (ec 2.6.1.2) (glutamic--pyruvic transaminase) (gpt) (glutamic--alanine transaminase). [source:swissprot;acc:p24298]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2415\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6956.62\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7223.09\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0383\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alanine aminotransferase 2; glutamic-pyruvate transaminase 2. [source:refseq;acc:nm\_133443]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2414\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6956.32\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7223.14\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.03836\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alanyl-trna synthetase (ec 6.1.1.7) (alanine--trna ligase) (alars). [source:swissprot;acc:p49588]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2599\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4367.69\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4438.77\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.01627\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alcohol dehydrogenase class iii chi chain (ec 1.1.1.1) (glutathione- dependent formaldehyde dehydrogenase) (ec 1.2.1.1) (fdh). [source:swissprot;acc:p11766]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2249\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6834.03\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7153.66\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.04677\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
aldehyde dehydrogenase 7 (ec 1.2.1.5). [source:swissprot;acc:p43353]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3222\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
aldehyde dehydrogenase 8 (ec 1.2.1.5). [source:swissprot;acc:p48448]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2992\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
aldehyde oxidase (ec 1.2.3.1). [source:swissprot;acc:q06278]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2960\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha adducin (erythrocyte adducin alpha subunit). [source:swissprot;acc:p35611]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1369\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5786.71\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6241.16\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07853\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha crystallin a chain. [source:swissprot;acc:p02489]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2875\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
alpha crystallin b chain (alpha(b)-crystallin) (rosenthal fiber component). [source:swissprot;acc:p02511]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3082\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha crystallin c chain (small stress protein-like protein hsp22) (e2ig1) (protein kinase h11). [source:swissprot;acc:q9ujy1]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2340\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5607.81\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5855.72\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.04421\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha enolase (ec 4.2.1.11) (2-phospho-d-glycerate hydro-lyase) (non- neural enolase) (nne) (enolase 1) (phosphopyruvate hydratase). [source:swissprot;acc:p06733]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
945\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6597.98\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7241\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.09746\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-(1,6)-fucosyltransferase (ec 2.4.1.68) (glycoprotein 6-alpha-l- fucosyltransferase) (gdp-fucose--glycoprotein fucosyltransferase) (gdp-l-fuc:n-acetyl-beta-d-glucosaminide alpha1,6-fucosyltransferase) (alpha1-6fuct) (fucosyltransferase 8). [source:swissprot;acc:q9byc5]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1544\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5466\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5865.33\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07306\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-1-acid glycoprotein 2 precursor (agp 2) (orosomucoid 2) (omd 2). [source:swissprot;acc:p19652]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2254\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
7383.13\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7727.39\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.04663\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-1-syntrophin (59 kda dystrophin-associated protein a1, acidic component 1) (pro-tgf-alpha cytoplasmic domain-interacting protein 1) (tacip1) (syntrophin 1). [source:swissprot;acc:q13424]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1772\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5829.61\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6218.27\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06667\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-actinin 1 (alpha-actinin cytoskeletal isoform) (non-muscle alpha-actinin 1) (f-actin cross linking protein). [source:swissprot;acc:p12814]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1345\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5887.88\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6354.47\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07925\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-actinin 2 (alpha actinin skeletal muscle isoform 2) (f-actin cross linking protein). [source:swissprot;acc:p35609]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1341\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5887.82\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6354.58\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07928\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-actinin 4 (non-muscle alpha-actinin 4) (f-actin cross linking protein). [source:swissprot;acc:o43707]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1346\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5887.89\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6354.45\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07924\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-centractin (centractin) (centrosome-associated actin homolog) (actin-rpv) (arp1). [source:swissprot;acc:p42024]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1151\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5322.74\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5793.15\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.08838\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-fetoprotein enhancer binding protein (at motif-binding factor) (at-binding transcription factor 1). [source:swissprot;acc:q15911]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2749\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
7776.91\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7783.48\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00084\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-nac protein. [source:sptrembl;acc:q9h009]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
704\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6912.27\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7734.68\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.11898\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-parvin (calponin-like integrin-linked kinase binding protein) (ch-ilkbp). [source:swissprot;acc:q9nvd7]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1867\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6076.66\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6463.12\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0636\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha-soluble nsf attachment protein (snap-alpha) (n-ethylmaleimide- sensitive factor attachment protein, alpha). [source:swissprot;acc:p54920]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2722\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5603.24\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5583.64\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00351\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alpha/beta hydrolase domain containing protein 1 isoform 2; lung alpha/beta hydrolase protein 1. [source:refseq;acc:nm\_152870]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1134\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
5790.65\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
6303.92\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.08864\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
alpha/beta hydrolase domain containing protein 3; lung alpha/beta hydrolase 3. [source:refseq;acc:nm\_138340]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1132\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
alveolar soft part sarcoma chromosome region, candidate 1; aspl protein; renal cell carcinoma gene on chromosome 17; renal cell carcinoma, papillary, 17 gene; aspscr1/tfe3 fusion gene, included. [source:refseq;acc:nm\_024083]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2829\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
amidophosphoribosyltransferase precursor (ec 2.4.2.14) (glutamine phosphoribosylpyrophosphate amidotransferase) (atase) (gpat). [source:swissprot;acc:q06203]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2550\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4725.79\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4824.4\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02087\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
aminoacylase-1 (ec 3.5.1.14) (n-acyl-l-amino-acid amidohydrolase) (acy-1). [source:swissprot;acc:q03154]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2349\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
8353.97\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8001.45\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.04406\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
aminoadipate-semialdehyde synthase; lysine-ketoglutarate reductase /saccharopine dehydrogenase; lysine-2-oxoglutarate reductase; aminoadipic semialdehyde synthase. [source:refseq;acc:nm\_005763]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
818\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6807.78\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7543.28\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.10804\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
aminomethyltransferase, mitochondrial precursor (ec 2.1.2.10) (glycine cleavage system t protein) (gcvt). [source:swissprot;acc:p48728]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1545\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5945.96\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6380.28\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07304\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
ammecr1 protein. [source:refseq;acc:nm\_015365]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1062\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5412.23\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5913.4\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0926\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
amp deaminase 2 (ec 3.5.4.6) (amp deaminase isoform l). [source:swissprot;acc:q01433]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
70\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6475.5\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
10307.5\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.59177\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
amyloid beta a4 precursor protein-binding family a member 1 (neuron- specific x11 protein) (neuronal munc18-1-interacting protein 1) (mint-1) (adapter protein x11alpha). [source:swissprot;acc:q02410]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
97\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
2820.51\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3897.1\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.3817\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
amyloid beta precursor protein-binding protein 1; amyloid protein-binding protein 1. [source:refseq;acc:nm\_003905]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1909\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6858.84\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
7287.27\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06246\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
amyloid beta precursor protein-binding protein 2; amyloid beta precursor protein (cytoplasmic tail)-binding protein 2; protein interacting with app tail 1. [source:refseq;acc:nm\_006380]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3191\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.00001\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
anaphase promoting complex subunit 11 (hepatocellular carcinoma associated ring finger protein) (hspc214). [source:swissprot;acc:q9nyg5]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2665\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
8936.97\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
8999.55\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.007\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
anaphase-promoting complex subunit 10; anaphase-promoting complex 10. [source:refseq;acc:nm\_014885]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1647\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
6079.19\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
6503.12\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.06973\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
anaphase-promoting complex subunit 2; anaphase-promoting complex 2. [source:refseq;acc:nm\_013366]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1518\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
10341.2\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
9630.35\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.07381\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
androgen-induced 1; cgi-103 protein; androgen induced protein. [source:refseq;acc:nm\_016108]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1969\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
4374.32\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4126.96\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.05994\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
angiomotin like 2; leman coiled-coil protein; angiomotin-like protein 2. [source:refseq;acc:nm\_016201]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1771\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
5829.61\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
6218.27\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.06667\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
angiomotin. [source:refseq;acc:nm\_133265]\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1770\vspace{3pt}}&&&\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/